Half Year 2025 Altamira Therapeutics Ltd Earnings Call Transcript
Key Points
- Altamira Therapeutics Ltd (CYTOF) is making significant progress in its RNA delivery business, focusing on nanoparticle formulation and process development.
- The company has successfully developed custom-sized batches of nanoparticles with greater stability, enhancing their shipping and storage capabilities.
- Altamira has expanded its partnerships, adding a fourth collaboration focused on circular RNA, which is a promising next-generation modality.
- The company has reduced its operating loss by 32.9% and net loss by 64.6% in the first half of 2025 compared to the same period in 2024.
- Altamira is transitioning its Bentrio nasal spray to a class 2A medical device under the EU's new medical device regulation, which is expected to boost commercialization efforts.
- Altamira Therapeutics Ltd (CYTOF) is facing challenges in raising funds from public markets, leading to a shift towards private equity investment.
- The company's cash and cash equivalents have significantly decreased from $1 million at the end of 2024 to $4,000 as of June 30, 2025.
- Shareholders' equity has declined from $6.6 million at year-end 2024 to $4.1 million as of June 30, 2025.
- The company is experiencing a higher pro rata loss for its associate Altamira Medica, increasing from $0.2 million to $0.5 million.
- Altamira's financial position remains constrained, with a reliance on subordinated loans and the planned partial spinoff of its RNA delivery subsidiary to manage operating expenses.
Good morning and welcome to the Altamira Therapeutics half year 2025 financial results and business update call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer, and Covadonga Paneda, Altamira's Chief Operating Officer.
Earlier today, Altamira issued a news release with the first half of 2025 financial results, as well as a business update. The release is available on the company's website at www.altamiratherapeutics.com and has been filed with the SEC.
During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995. These include statements that address future operating, financial or business performance or its strategies or expectations.
Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
